$MNPR
Monopar Therapeutics Inc

2023 Q1 Form 10-K Financial Statement

#000165495423003384 Filed on March 23, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $871.7K $808.7K $2.945M
YoY Change 11.86% 15.79% 11.82%
% of Gross Profit
Research & Development $1.653M $2.103M $7.592M
YoY Change -1.46% 6.07% 16.92%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.525M $2.909M $10.54M
YoY Change 2.76% 8.5% 15.44%
Operating Profit -$2.525M -$10.54M
YoY Change 2.76% 15.44%
Interest Expense $90.49K $12.66K $21.24K
YoY Change 19571.74% 2288.68% -11.57%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.435M -$2.896M -$10.52M
YoY Change -0.9% 8.05% 15.52%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.435M -$2.896M -$10.52M
YoY Change -0.9% 8.05% 15.52%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19 -$0.83
Diluted Earnings Per Share -$0.19 -$0.22 -$0.83
COMMON SHARES
Basic Shares Outstanding 13.19M shares 12.86M shares 12.72M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.68M $13.12M $13.12M
YoY Change -34.47% -35.38% -35.38%
Cash & Equivalents $5.726M $8.186M $8.186M
Short-Term Investments $5.951M $4.934M $4.934M
Other Short-Term Assets $106.8K $45.98K $45.98K
YoY Change -44.84% -78.88% -78.88%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.78M $13.17M $13.17M
YoY Change -34.58% -35.84% -35.84%
LONG-TERM ASSETS
Property, Plant & Equipment $49.38K $61.23K $61.23K
YoY Change -8.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $49.38K $61.23K $61.22K
YoY Change -8.04%
TOTAL ASSETS
Total Short-Term Assets $11.78M $13.17M $13.17M
Total Long-Term Assets $49.38K $61.23K $61.22K
Total Assets $11.83M $13.23M $13.23M
YoY Change -34.51% -35.55% -35.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.888M $3.080M $3.080M
YoY Change 175.51% 94.89% 94.89%
Accrued Expenses $48.58K $48.58K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.888M $3.129M $3.129M
YoY Change 168.85% 97.96% 97.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $8.410K $8.410K
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $8.410K $8.410K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.888M $3.129M $3.129M
Total Long-Term Liabilities $0.00 $8.410K $8.410K
Total Liabilities $2.888M $3.137M $3.137M
YoY Change 162.65% 98.5% 98.5%
SHAREHOLDERS EQUITY
Retained Earnings -$54.24M -$51.80M
YoY Change 25.47%
Common Stock $13.22K $12.95K
YoY Change 2.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.945M $10.09M $10.09M
YoY Change
Total Liabilities & Shareholders Equity $11.83M $13.23M $13.23M
YoY Change -34.51% -35.55% -35.55%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$2.435M -$2.896M -$10.52M
YoY Change -0.9% 8.05% 15.52%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.271M -$1.302M -$7.229M
YoY Change -7.96% -35.93% -198.79%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$983.4K -$4.919M -$4.919M
YoY Change
Cash From Investing Activities -$983.4K -$4.919M -$4.919M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $804.8K 138.7K $32.87K
YoY Change -4928.98% -1885.46% -99.7%
NET CHANGE
Cash From Operating Activities -$2.271M -1.302M -$7.229M
Cash From Investing Activities -$983.4K -4.919M -$4.919M
Cash From Financing Activities $804.8K 138.7K $32.87K
Net Change In Cash -$2.461M -6.082M -$12.12M
YoY Change -0.95% 198.17% -166.59%
FREE CASH FLOW
Cash From Operating Activities -$2.271M -$1.302M -$7.229M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
169 usd
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17478 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8186194 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20303869 usd
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001645469
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12598125 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12946573 shares
mnpr Fees And Commission
FeesAndCommission
591188 usd
CY2021Q4 mnpr Common Stock Issued And Oustanding
CommonStockIssuedAndOustanding
12946573 shares
CY2021 mnpr Operating Lease Weighted Average Remaining Lease Terms1
OperatingLeaseWeightedAverageRemainingLeaseTerms1
P0Y
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-39070
CY2022 dei Entity Registrant Name
EntityRegistrantName
MONOPAR THERAPEUTICS INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0463781
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
1000 Skokie Blvd.
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 350
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Wilmette
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
60091
CY2022 dei City Area Code
CityAreaCode
847
CY2022 dei Local Phone Number
LocalPhoneNumber
388-0349
CY2022 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
CY2022 dei Trading Symbol
TradingSymbol
MNPR
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
10000462 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13193172 shares
CY2022 dei Auditor Firm
AuditorFirmId
207
CY2022 dei Auditor Name
AuditorName
BPM LLP
CY2022 dei Auditor Location
AuditorLocation
Walnut Creek, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8186194 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20303869 usd
CY2022Q4 us-gaap Investments
Investments
4933550 usd
CY2021Q4 us-gaap Investments
Investments
0 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
45982 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
217745 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
13165726 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
20521614 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
61228 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2022Q4 us-gaap Assets
Assets
13226954 usd
CY2021Q4 us-gaap Assets
Assets
20521614 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3128894 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1580543 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3128894 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1580543 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8408 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3137302 usd
CY2021Q4 us-gaap Liabilities
Liabilities
1580543 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12946573 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12598125 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12947 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
12598 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
61871784 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60220016 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8942 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3160 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51804021 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41288383 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10089652 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18941071 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13226954 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20521614 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7591601 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6493208 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2945276 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2634040 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
10536877 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
9127248 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-10536877 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-9127248 usd
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
21239 usd
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
24024 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-10515638 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-9103224 usd
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-2937 usd
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
4713 usd
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
15039 usd
CY2021 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 usd
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10503536 usd
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9098511 usd
CY2022 mnpr Basic And Diluted
BasicAndDiluted
-0.83
CY2021 mnpr Basic And Diluted
BasicAndDiluted
-0.73
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12718166 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12471217 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15691991 usd
CY2021 mnpr Issuance Of Common Stock Under A Capital On Demandtm Sales Agreement With Jonestrading Institutional Services Llc Net Of Commissions And Fees Three Three Eight One Five Three Amount
IssuanceOfCommonStockUnderACapitalOnDemandtmSalesAgreementWithJonestradingInstitutionalServicesLlcNetOfCommissionsAndFeesThreeThreeEightOneFiveThreeAmount
10925312 usd
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2021 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-63253 usd
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17478 usd
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1468054 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-9103224 usd
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4713 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18941071 usd
CY2022 mnpr Issuance Of Common Stock Under A Capital On Demandtm Sales Agreement With Jonestrading Institutional Services Llc Net Of Commissions Fees And Expenses Of87611 Amount
IssuanceOfCommonStockUnderACapitalOnDemandtmSalesAgreementWithJonestradingInstitutionalServicesLlcNetOfCommissionsFeesAndExpensesOf87611Amount
87318 usd
CY2022 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2022 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-76633 usd
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
169 usd
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1641263 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-10515638 usd
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
12102 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10089652 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-10515638 usd
CY2021 us-gaap Profit Loss
ProfitLoss
-9103224 usd
CY2022 mnpr Stock Based Compensation Expense Non Cash
StockBasedCompensationExpenseNonCash
1641263 usd
CY2021 mnpr Stock Based Compensation Expense Non Cash
StockBasedCompensationExpenseNonCash
1468054 usd
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
171755 usd
CY2021 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-86198 usd
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1478299 usd
CY2021 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
403967 usd
CY2022 mnpr Operating Lease Right Of Use Assets And Liabilities Net
OperatingLeaseRightOfUseAssetsAndLiabilitiesNet
-4238 usd
CY2021 mnpr Operating Lease Right Of Use Assets And Liabilities Net
OperatingLeaseRightOfUseAssetsAndLiabilitiesNet
0 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7228559 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7317401 usd
CY2022 us-gaap Net Investment In Lease Purchase
NetInvestmentInLeasePurchase
4918511 usd
CY2021 us-gaap Net Investment In Lease Purchase
NetInvestmentInLeasePurchase
0 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4918511 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022 mnpr Cash Proceeds From The Sales Of Common Stock Under A Capital
CashProceedsFromTheSalesOfCommonStockUnderACapital
109337 usd
CY2021 mnpr Cash Proceeds From The Sales Of Common Stock Under A Capital
CashProceedsFromTheSalesOfCommonStockUnderACapital
10925312 usd
CY2022 mnpr Taxes Paid Related To Net Share Settlement Of Vested Restricted Stock Units
TaxesPaidRelatedToNetShareSettlementOfVestedRestrictedStockUnits
-76633 usd
CY2021 mnpr Taxes Paid Related To Net Share Settlement Of Vested Restricted Stock Units
TaxesPaidRelatedToNetShareSettlementOfVestedRestrictedStockUnits
-63253 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32873 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10879537 usd
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
-3478 usd
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
4624 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12117675 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3566760 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20303869 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16737109 usd
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 1 - Nature of Business and Liquidity</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Nature of Business</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Monopar Therapeutics Inc. (“Monopar” or the ”Company”) is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve quality of life for cancer patients. Monopar currently has four compounds in development: 1) Validive<sup style="vertical-align:super">®</sup> (clonidine hydrochloride mucobuccal tablet; clonidine HCI MBT), a Phase 2b/3 clinical stage, first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (“SOM”) in oropharyngeal cancer patients; 2) camsirubicin (generic name for MNPR-201, GPX-150; 5-imino-13-deoxydoxorubicin), a Phase 1b clinical stage novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; 3) MNPR-101 RIT and MNPR-101-Zr, a preclinical stage uPAR-targeted antibody being developed as a radioimmunotherapeutic and companion diagnostic for advanced cancers; and 4) an early stage camsirubicin analog, MNPR-202, for various cancers. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Liquidity</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has incurred an accumulated deficit of approximately $51.8 million as of December 31, 2022. To date, the Company has primarily funded its operations with the net proceeds from the Company’s initial public offering of its common stock on Nasdaq, sales of its common stock in the public market through at-the-market sales agreements, private placements of convertible preferred stock and of common stock and cash provided in the camsirubicin asset purchase transaction. Management estimates that currently available cash will provide sufficient funds to enable the Company to meet its obligations at least through March 2024. The Company’s ability to fund its future operations, including the continued clinical development of Validive and camsirubicin, is dependent upon its ability to execute its business strategy, to obtain additional funding and/or to execute collaborative research agreements. There can be no certainty that future financing or collaborative research agreements will occur in the amounts required or at a time needed to maintain operations, if at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The coronavirus disease (“COVID-19”) continues to affect economies and business around the world. In response to COVID-19 and its effects on clinical trials, in 2020 Monopar modified the original adaptive design Phase 3 clinical trial for its lead product candidate, Validive, to be a Phase 2b/3 clinical trial (“VOICE”) to better fit the types of trials which can enroll sufficient required patients in the current environment. This modification allowed the Company to activate the VOICE clinical trial without requiring near-term financing. To complete the VOICE clinical program, including, if required, completing a second Phase 3 confirmatory clinical trial, Monopar will require additional funding in the millions or tens of millions of dollars (depending on if the Company has consummated a collaboration or partnership or neither for Validive), which it is planning to pursue within the next 12 months. Due to many uncertainties, the Company is unable to estimate COVID-19’s financial impact or duration in light of global vaccine rollouts, treatment options and potential surges of new cases from current or future COVID-19 variants or its potential impact on the Company’s current clinical trials, including COVID-19’s effect on drug candidate manufacturing, shipping, patient recruitment at clinical sites and regulatory agencies around the globe. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Russia-Ukraine war, and resulting sanctions against Russia and Russian entities or allies, have increased fuel costs and may cause shipping delays. The broader economic, trade and financial market consequences are uncertain at this time, which may increase the cost of supplies for the Company’s clinical materials, may delay the manufacture of its clinical materials, may increase costs of other goods and services, or make it more difficult or costly to raise additional financing, any of which could cause an adverse effect on the Company’s clinical programs and on the Company’s financial condition. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Market variables, such as inflation of product costs, higher capital costs, labor rates and fuel, freight and energy costs, as well as geopolitical events could likely cause the Company to suffer significant increases in its operating and administrative expenses.</p>
CY2022Q4 mnpr Accumulated Deficit
AccumulatedDeficit
51800000 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. </p>
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1655451 shares
CY2022Q4 mnpr Insurance Premiums Dues Subscription And Software Cost Paid In Advance
InsurancePremiumsDuesSubscriptionAndSoftwareCostPaidInAdvance
10000 usd
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents at two reputable financial institutions. As of December 31, 2022, the balance at one financial institution was in excess of the $250,000 Federal Deposit Insurance Corporation (“FDIC”) insurable limit. The Company has not experienced any losses on its deposits since inception and management believes the Company is not exposed to significant risks with respect to these financial institutions.</p>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
7248946 usd
CY2022Q4 us-gaap Investments
Investments
4933550 usd
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
12182496 usd
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
20014205 usd
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
20014205 usd
CY2022 mnpr Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
12718166 shares
CY2021 mnpr Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
12472217 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1915600 shares
CY2022Q4 mnpr Net Amortized Cost Basis
NetAmortizedCostBasis
12167457 usd
CY2022Q4 mnpr Investments Gross Unrealized Gain Before Tax
InvestmentsGrossUnrealizedGainBeforeTax
15039 usd
CY2022Q4 mnpr Net Aggregate Fair Value
NetAggregateFairValue
12182496 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
4900000 usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022 mnpr Common Stock Aggregate Offering Price Description
CommonStockAggregateOfferingPriceDescription
up to $19.7
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1964724 shares
mnpr Average Gross Price Per Share
AverageGrossPricePerShare
10.02
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
19100603 usd
CY2022Q2 mnpr Pursuant Aggregate Amount
PursuantAggregateAmount
4870000 usd
CY2022 mnpr Aggregate Amount Increased
AggregateAmountIncreased
6680571 usd
CY2022 mnpr Capital Amount Sold
CapitalAmountSold
174929 usd
CY2022 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
64573 shares
CY2022 mnpr Average Gross Price Per Share
AverageGrossPricePerShare
2.71
CY2022 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
170552 usd
CY2022 mnpr Fees And Commission
FeesAndCommission
4377 usd
CY2022 us-gaap Landing Fees And Other Rentals
LandingFeesAndOtherRentals
83234 usd
CY2022 mnpr Net Proceeds After Fees Commissions And Expenses
NetProceedsAfterFeesCommissionsAndExpenses
87318 usd
CY2022Q4 mnpr Common Stock Issued And Oustanding
CommonStockIssuedAndOustanding
12946573 shares
CY2022 mnpr Description Of Exercise Price
DescriptionOfExercisePrice
exercise prices ranging from $1.59 to $3.95 per share which vest over 1 to 4 years. All stock option grants have a 10-year term
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
403522 shares
CY2022 mnpr Stock Option Grants Term Period
StockOptionGrantsTermPeriod
P10Y
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1258577 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.47
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
403476 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.27
CY2021 mnpr Stock Options Forfeite
StockOptionsForfeite
-115151 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.49
CY2021 mnpr Stock Options Exercised
StockOptionsExercised
-2913 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.00
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1543989 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.78
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
604064 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.83
CY2022 mnpr Stock Options Forfeite
StockOptionsForfeite
-337103 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.13
CY2022 mnpr Stock Options Exercised
StockOptionsExercised
-168000 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.001
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1642950 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.28
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
461524 shares
CY2022 mnpr Weighted Average Exercise Price Unvested Options Outstanding Expected To Vest
WeightedAverageExercisePriceUnvestedOptionsOutstandingExpectedToVest
4.00
CY2022 mnpr Stock Option Granted
StockOptionGranted
604064 shares
CY2022Q4 mnpr Number Of Shares Subject To Options Outstanding
NumberOfSharesSubjectToOptionsOutstanding
1642950 shares
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M24D
CY2022Q4 mnpr Number Of Shares Subjected To Fully Vested And Exercisable
NumberOfSharesSubjectedToFullyVestedAndExercisable
1181426 shares
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M10D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
604064 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
403476 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.13
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.46
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
970451 usd
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
1152572 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
917798 usd
CY2022 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
2690 shares
CY2022Q4 mnpr Weighted Average Exercise Price
WeightedAverageExercisePrice
4.28
CY2022Q4 mnpr Weighted Average Vested Exercise Price
WeightedAverageVestedExercisePrice
4.39
CY2022Q4 mnpr Weighted Average Stock Options Expected To Vest
WeightedAverageStockOptionsExpectedToVest
4.00
CY2022Q4 mnpr Unamortized Unvested Balance Of Stock Base Compensation
UnamortizedUnvestedBalanceOfStockBaseCompensation
2200000 usd
CY2022 mnpr Unamortized Unvested Balance Of Stock Base Compensation Period
UnamortizedUnvestedBalanceOfStockBaseCompensationPeriod
P2Y7M6D
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3421000 usd
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2500000 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 usd
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 usd
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0 usd
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0 usd
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0639 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0712 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0557 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0203 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0245 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0197 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3258 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2747 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0206 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0071 pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0001 pure
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3548494 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3484229 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1254678 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
382648 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
630113 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
700208 usd
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3824482 usd
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3153199 usd
CY2022Q4 mnpr Accrued Liabilities Allowances
AccruedLiabilitiesAllowances
96478 usd
CY2021Q4 mnpr Accrued Liabilities Allowances
AccruedLiabilitiesAllowances
0 usd
CY2022Q4 mnpr Capitalized Research And Development
CapitalizedResearchAndDevelopment
1787350 usd
CY2021Q4 mnpr Capitalized Research And Development
CapitalizedResearchAndDevelopment
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11141595 usd
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7720284 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11141595 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7720284 usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2022 mnpr Beginning Uncertain Tax Benefits Balance
BeginningUncertainTaxBenefitsBalance
103104 usd
CY2021 mnpr Beginning Uncertain Tax Benefits Balance
BeginningUncertainTaxBenefitsBalance
63262 usd
CY2022 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
150701 usd
CY2021 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
46092 usd
CY2022 mnpr Prior Year Increases Decreases
PriorYearIncreasesDecreases
67370 usd
CY2021 mnpr Prior Year Increases Decreases
PriorYearIncreasesDecreases
-6250 usd
CY2022 mnpr Ending Uncertain Tax Benefits
EndingUncertainTaxBenefits
321175 usd
CY2021 mnpr Ending Uncertain Tax Benefits
EndingUncertainTaxBenefits
103104 usd
CY2022Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
321175 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
34424 usd
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
54960 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
50856 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8476 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
59332 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2342 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
56990 usd
CY2022 mnpr Operating Lease Weighted Average Remaining Lease Terms1
OperatingLeaseWeightedAverageRemainingLeaseTerms1
P1Y2M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0650 pure
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0 pure
CY2022Q4 mnpr Operatingleaserightofuseassetnoncurrent
Operatingleaserightofuseassetnoncurrent
61228 usd
CY2021Q4 mnpr Operatingleaserightofuseassetnoncurrent
Operatingleaserightofuseassetnoncurrent
0 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
61228 usd
CY2022Q4 mnpr Operating Leases Liability Current
OperatingLeasesLiabilityCurrent
48582 usd
CY2021Q4 mnpr Operating Leases Liability Current
OperatingLeasesLiabilityCurrent
0 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8408 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
56990 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
0 usd

Files In Submission

Name View Source Status
0001654954-23-003384-index-headers.html Edgar Link pending
0001654954-23-003384-index.html Edgar Link pending
0001654954-23-003384.txt Edgar Link pending
0001654954-23-003384-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mnpr-20221231.xsd Edgar Link pending
mnpr_10k.htm Edgar Link pending
mnpr_10kimg1.jpg Edgar Link pending
mnpr_10kimg12.jpg Edgar Link pending
mnpr_10kimg13.jpg Edgar Link pending
mnpr_10kimg14.jpg Edgar Link pending
mnpr_10kimg15.jpg Edgar Link pending
mnpr_10kimg16.jpg Edgar Link pending
mnpr_10kimg17.jpg Edgar Link pending
mnpr_10kimg18.jpg Edgar Link pending
mnpr_10kimg3.jpg Edgar Link pending
mnpr_10kimg4.jpg Edgar Link pending
mnpr_10kimg8.jpg Edgar Link pending
mnpr_ex101.htm Edgar Link pending
mnpr_ex211.htm Edgar Link pending
mnpr_ex231.htm Edgar Link pending
mnpr_ex311.htm Edgar Link pending
mnpr_ex312.htm Edgar Link pending
mnpr_ex321.htm Edgar Link pending
mnpr_ex41.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
mnpr-20221231_cal.xml Edgar Link unprocessable
mnpr-20221231_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
mnpr-20221231_lab.xml Edgar Link unprocessable
mnpr-20221231_pre.xml Edgar Link unprocessable
mnpr_10k_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending